At a glance
ClinicalIndex Comparison RecordN/ACompleted· 301 enrolled
Drug / intervention
APOE Disclosurebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Genetic Risk Assessment and Counseling for Alzheimer's Disease
National Human Genome Research Institute (NHGRI)·interventional·Posted Dec 11, 2007·Updated Jul 23, 2009
In Brief
A clinical study evaluating APOE Disclosure for Alzheimer's Disease. Completed, enrolled 301 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine the characteristics of those who obtain genetic susceptibility testing for Alzheimer's disease with APOE disclosure and to study the psychological and behavioral consequences of providing this information.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
N/ACompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2000
Study CompletionApr 2004
First PostedDec 2007
TodayJul 2026
First PostedDec 11, 2007
Enrollment StartAug 1, 2000
Study CompletionApr 1, 2004
TodayJul 2, 2026
Posted 18.6 years ago
Interventions
APOE Disclosurebehavioral
Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.